Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: NEC Clear all
Recruiting Phase 1Phase 2 Interventional

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

NCT07174583
View directory record Official record
Conditions
Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
Interventions
IDE849, durvalumab, IDE161, Carboplatin
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
Denver, Colorado • Orlando, Florida • Fort Wayne, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Not applicable Interventional

Real-time Computer-Aided Detection of Colonic Adenomas With NEC WISE VISION® Endoscopy

NCT05611151
View directory record Official record
Conditions
Colorectal Cancer, Adenoma Colon, Polyp of Colon
Interventions
Computer Aided Detection (CADe)
Diagnostic Test
Lead sponsor
NEC Corporation
Industry
Eligibility
45 Years to 75 Years
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 5, 2026, 10:52 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

NCT03944772
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab, Carboplatin, Pemetrexed, Alectinib, Selpercatinib, Selumetinib, Etoposide, Cisplatin, Datopotamab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Early Phase 1 Interventional

Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy

NCT01306838
View directory record Official record
Conditions
Short Bowel Syndrome, Necrotizing Enterocolitis, Small Intestine Perforation
Interventions
MicroLipid and fish oil, Routine care
Dietary Supplement · Other
Lead sponsor
Wake Forest University
Other
Eligibility
1 Day to 60 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants

NCT01576003
View directory record Official record
Conditions
Bloodstream Infections, Short Bowel Syndrome, Development, Nutrition, Biological Markers
Interventions
Glutamine, L-alanine
Drug · Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Weeks to 12 Months
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 5, 2026, 10:52 AM EDT
Terminated Not applicable Interventional Results available

NEC Screening Abdominal Radiograph vs Bowel Ultrasound in Preemies

NCT03963011
View directory record Official record
Conditions
Enterocolitis, Necrotizing, Premature Infant
Interventions
Bowel Ultrasound
Diagnostic Test
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 28 Weeks
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Sep 5, 2026, 10:52 AM EDT
Completed No phase listed Observational

Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis

NCT00059449
View directory record Official record
Conditions
Necrotizing Enterocolitis, Premature Birth
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Up to 72 Hours
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Sep 5, 2026, 10:52 AM EDT
Recruiting Phase 2 Interventional

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

NCT06406465
View directory record Official record
Conditions
Carcinoma, Neuroendocrine, Tumor, Neuroendocrine, Tumors, Neuroendocrine, Neuroendocrine; Carcinoma, Small Cell; Receptors
Interventions
Belinostat, Cisplatin, Etoposide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Not applicable Interventional

Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer

NCT01975363
View directory record Official record
Conditions
Atypical Ductal Breast Hyperplasia, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions
curcumin, Biomarker analysis, Assessment of Dietary Intake, Daily Log
Dietary Supplement · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Sep 5, 2026, 10:52 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Impact of Feeding on Pro-Inflammatory Cytokine Response in Neonates Receiving a RBC Transfusion

NCT01949896
View directory record Official record
Conditions
Transfusions
Interventions
NPO, Control group: continue feedings
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
3 Days to 6 Months
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Sep 5, 2026, 10:52 AM EDT
Active, not recruiting Phase 2 Interventional

RIC-NEC Randomized Controlled Trial

NCT05279664
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
Remote ischemic conditioning (RIC) + Standard of Care for NEC, Standard of Care for NEC
Other
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
0 Weeks and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 5, 2026, 10:52 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

NCT04514497
View directory record Official record
Conditions
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Neuroendocrine Carcinoma, Unresectable Pancreatic Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Elimusertib, Irinotecan Hydrochloride, Magnetic Resonance Imaging, Topotecan Hydrochloride
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Phoenix, Arizona • Orange, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 5, 2026, 10:52 AM EDT
Withdrawn Not applicable Interventional

Utility of Bowel Ultrasound in Diagnosing Necrotizing Eneterocolitis in Congenital Heart Disease

NCT03142685
View directory record Official record
Conditions
Enterocolitis, Necrotizing, Congenital Heart Disease
Interventions
Bowel Ultrasound
Device
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 6 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Not applicable Interventional Results available

Collaborative Research Group for Necrotizing Enterocolitis

NCT00828451
View directory record Official record
Conditions
Prematurity, Necrotizing Enterocolitis
Interventions
[5,5,5-2H3]leucine (stable isotope labeled leucine)
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Day to 7 Days
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

NCT03136055
View directory record Official record
Conditions
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Interventions
Pembrolizumab, Irinotecan, Paclitaxel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
San Francisco, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2022 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Not applicable Interventional

Comparison of Two Surgical Treatments for Necrotizing Enterocolitis in Human Infants

NCT00252681
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
laparotomy, primary peritoneal drainage
Procedure
Lead sponsor
Yale University
Other
Eligibility
0 Years to 3 Months
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 20, 2006 · Synced Sep 5, 2026, 10:52 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Early Predictors of Necrotizing Enterocolitis in Neonates

NCT03210831
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
Not listed
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 7 Days
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 5, 2026, 10:52 AM EDT
Completed No phase listed Observational

Registry for Study of Coils in Intracranial Aneurysms

NCT01000675
View directory record Official record
Conditions
Cerebral Aneurysms
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 90 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Sep 5, 2026, 10:52 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

SMOFlipid to Lessen the Severity of Neonatal Cholestasis

NCT02721277
View directory record Official record
Conditions
Cholestasis, Jaundice, Obstructive
Interventions
SMOFlipid
Drug
Lead sponsor
University of Florida
Other
Eligibility
23 Weeks to 1 Year
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 5, 2026, 10:52 AM EDT
Active, not recruiting Phase 3 Interventional

IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

NCT03978000
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
IBP-9414, Placebo
Drug
Lead sponsor
Infant Bacterial Therapeutics
Industry
Eligibility
Up to 48 Hours
Enrollment
2,158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
54
States / cities
Tucson, Arizona • Little Rock, Arkansas • Loma Linda, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Sep 5, 2026, 10:52 AM EDT
Terminated Not applicable Interventional Results available

Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants

NCT01156480
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
hydrocortisone, placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
0 Days to 6 Months
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 5, 2026, 10:52 AM EDT
Terminated Phase 3 Interventional Results available

CEUS Evaluation of Bowel Perfusion in Necrotizing Enterocolitis

NCT03549507
View directory record Official record
Conditions
Necrotizing Enterocolitis of Newborn, Bowel Ischemic
Interventions
Sulfur hexafluoride lipid-type A microspheres
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 18 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Phase 3 Interventional

Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)

NCT00009646
View directory record Official record
Conditions
Infant, Very Low Birth Weight, Infant, Premature, Ductus Arteriosus, Patent
Interventions
Indomethacin, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
2 Hours to 6 Hours
Enrollment
1,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
9
States / cities
Birmingham, Alabama • Palo Alto, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 5, 2026, 10:52 AM EDT
Completed No phase listed Observational

Prediction of Feeding Problems in Prostaglandin-dependent Prematurely Born Infants With Congenital Heart Disease

NCT01126372
View directory record Official record
Conditions
Congenital Heart Disease, Prematurity, Necrotizing Enterocolitis
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Up to 1 Month
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Sep 5, 2026, 10:52 AM EDT